A Comparison of Electrospun Polymers Reveals Poly(3-Hydroxybutyrate) Fiber as a Superior Scaffold for Cardiac Repair

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Blanes M
  • Pelacho B
  • Araña M
  • Prosper F

Grups d'Investigació

Abstract

The development of biomaterials for myocardial tissue engineering requires a careful assessment of their performance with regards to functionality and biocompatibility, including the immune response. Poly(3-hydroxybutyrate) (PHB), poly(e-caprolactone) (PCL), silk, poly-lactic acid (PLA), and polyamide (PA) scaffolds were generated by electrospinning, and cell compatibility in vitro, and immune response and cardiac function in vitro and in vivo were compared with a noncrosslinked collagen membrane (Col) control material. Results showed that cell adhesion and growth of mesenchymal stem cells, cardiomyocytes, and cardiac fibroblasts in vitro was dependent on the polymer substrate, with PHB and PCL polymers permitting the greatest adhesion/growth of cells. Additionally, polymer substrates triggered unique expression profiles of anti- and pro-inflammatory cytokines in human peripheral blood mononuclear cells. Implantation of PCL, silk, PLA, and PA patches on the epicardial surface of healthy rats induced a classical foreign body reaction pattern, with encapsulation of polymer fibers and induction of the nonspecific immune response, whereas Col and PHB patches were progressively degraded. When implanted on infarcted rat heart, Col, PCL, and PHB reduced negative remodeling, but only PHB induced significant angiogenesis. Importantly, Col and PHB modified the inflammatory response to an M2 macrophage phenotype in cardiac tissue, indicating a more beneficial reparative process and remodeling. Collectively, these results identify PHB as a superior substrate for cardiac repair.

Dades de la publicació

ISSN/ISSNe:
1547-3287, 1557-8534

STEM CELLS AND DEVELOPMENT  MARY ANN LIEBERT, INC

Tipus:
Article
Pàgines:
1479-1490
PubMed:
24564648
Factor d'Impacte:
1,625 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 68

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Projectes associats

REDINSCOR

RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008

RED DE BIOBANCOS (BIOBANCOS)

RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

CREACION Y MEJORA DE INFRAESTRUCTURAS EN MEDICINA REGENERATIVA

Investigador Principal: FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA

PLE2009-0141 ACI-PLAN E . MINISTERIO DE CIENCIA E INNOVACION; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009

REGISTRO MULTICÉNTRICO DE PACIENTES HOSPITALIZADOS POR INSUFICIENCIA CARDÍACA AGUDA (REDINSCOR II).

RD12/0042/0003 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

RED DE TERAPIA CELULAR (TERCEL)

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

RD12/0019/0025 . INSTITUTO DE SALUD CARLOS III; FUNDACION FORMACION E INVESTIGACIÓN SANITARIA MURCIA (IMIB); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013

MECANISMOS MOLECULARES Y CELULARES DE LAS CELULAS MESENQUIMALES HUMANAS Y DE LAS CELULAS CARDIACAS RESIDENTES DEL ADULTO EN EL ENTORNO CARDIACO ISQUEMICO Y EL NICHO HEMATOPOYETICO.

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

PI13/00414 . INSTITUTO DE SALUD CARLOS III . 2014

ESTUDIO DE DURABILIDAD DEL TRIFECTA.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CS-10-012-EU-TV . 2011

ESTUDIO DE LA TOXICIDAD EN PLASMA INDUCIDA POR AGENTES QUIMIOTERÁPICOS.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CARDIOTOX CLÍNICO

Compartir la publicació